Author

S. Hofer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Organism:mouse· 1

Frequent Co-Authors

A. Christiansen· 1 shared A. E. Casey· 1 shared A. Sakhteman· 1 shared B. Kuster· 1 shared B. Wang· 1 shared C. Chen· 1 shared C. Fankhauser· 1 shared C. Fritz· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Christiansen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response

S. Hofer, L. Frasch, K. Putzker, J. Lewis, A. Sakhteman, M. The, F. P. Bayer, J. Muller, F. Hamood, B. Kuster

This study identifies ATR inhibitors as synergistic with gemcitabine in killing PDAC cells by blocking the DNA damage response pathway.

bioRxiv · Mar 22, 2024Cancer Biology

Mammary lineage dictates homologous recombination repair and PARP inhibitor vulnerability

H. Kim, A. E. Casey, L. Palomero, M. Mahendralingam, M. Parsons, S. Narala, F. Mateo, S. Hofer, P. D. Waterhouse, T. Kislinger, M. A. Pujana, H. K. Berman, R. Khokha

The paper shows that mammary epithelial lineage determines HR and PARP inhibitor vulnerability, with luminal cells having high-fidelity HR and PARPi sensitivity.

bioRxiv · May 14, 2021 · PreprintCancer Biology

High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification

Y. J. Zhu, T. Weiss, Q. Zhang, R. Sun, B. Wang, Z. Wu, Q. Zhong, X. Yi, H. Gao, X. Cai, G. Ruan, T. Zhu, C. Xu, S. Lou, X. Yu, , T. Guo

This study develops a proteomic workflow for FFPE tissues to stratify prostate cancer and DLBCL samples, identifying MPO as a prognostic marker and showing FFPE's utility for biomarker discovery.

bioRxiv · Jun 11, 2019Biochemistry